ATRA · Atara Biotherapeutics Inc. Common Stock
View on chartInsiders & Stakes
| EcoR1 Capital, LLC 10% Owner | ▲ Buy | Open Market | 1,552,000 Shares held | 5/7/2026 | View profile |
| Adiumentum Capital Fund I LP Director | ▲ Buy | Grant | 1,209,395 Shares held | 5/16/2025 | View profile |
| Panacea Innovation Ltd | ▼ Sell | Open Market | 1,011,000 Shares held | 5/7/2026 | View profile |
| Redmile Group, LLC 10% Owner | ▼ Sell | Tax Withholding | 636,852 Shares held | 7/22/2026 | View profile |
| Eric Dobmeier | ▲ Buy | Open Market | 563,325 Shares held | 11/10/2023 | View profile |
| Dupont Jakob EVP, Head of R&D | ▼ Sell | Open Market | 290,794 Shares held | 3/2/2023 | View profile |
| Banard Charlene A. EVP, Chief Technical Officer | ▼ Sell | Open Market | 276,010 Shares held | 5/16/2023 | View profile |
| Koppikar Utpal Director | ▼ Sell | Open Market | 181,978 Shares held | 3/2/2023 | View profile |
| Kristin Yarema Chief Executive Officer | ▲ Buy | Grant | 171,415 Shares held | 3/1/2022 | View profile |
| Joshi Manher EVP, Chief Medical Officer | ▼ Sell | Open Market | 171,284 Shares held | 11/16/2023 | View profile |
| Brian N. Cherry | ▲ Buy | Open Market | 166,486 Shares held | 9/4/2026 | View profile |
| AnhCo Nguyen President and CEO | ▼ Sell | Open Market | 132,775 Shares held | 8/17/2026 | View profile |
| Beth C. Seidenberg Director | ▲ Buy | Grant | 115,689 Shares held | 5/31/2023 | View profile |
| Newell Joe Chief Operations Officer | ▼ Sell | Open Market | 113,097 Shares held | 11/16/2021 | View profile |
| Pascal Touchon President and CEO | ▲ Buy | Grant | 77,955 Shares held | 6/10/2025 | View profile |
| Eric J. Hyllengren SVP, CFO | ▼ Sell | Open Market | 56,231 Shares held | 3/3/2025 | View profile |
| Yanina Grant-Huerta Chief Financial Officer | ▼ Sell | Open Market | 49,636 Shares held | 5/18/2026 | View profile |
| Roy D. Baynes Director | ▲ Buy | Grant | 43,500 Shares held | 6/23/2022 | View profile |
| William K. Heiden Director | ▲ Buy | Grant | 34,188 Shares held | 6/9/2026 | View profile |
| Carol Giltner Gallagher | ▲ Buy | Grant | 33,012 Shares held | 6/10/2025 | View profile |
| Ronald C. Renaud Jr. CEO & President | ▲ Buy | Grant | 31,500 Shares held | 6/23/2022 | View profile |
| Matthew K. Fust Director | ▲ Buy | Grant | 30,188 Shares held | 6/9/2026 | View profile |
| Murugan Amar SVP, GC & Secretary | ▼ Sell | Open Market | 26,827 Shares held | 8/16/2024 | View profile |
| Jill Henrich EVP, Global Head RA & Quality | ▼ Sell | Open Market | 18,679 Shares held | 3/3/2025 | View profile |
| Maria Grazia Roncarolo | ▲ Buy | Grant | 17,368 Shares held | 6/10/2025 | View profile |
| Ameet Mallik Director | ▲ Buy | Grant | 16,928 Shares held | 6/10/2025 | View profile |
| Gregory Austin Ciongoli | ▲ Buy | Grant | 12,000 Shares held | 6/9/2026 | View profile |
Transaction History
| Brian N. Cherry | ▲ Buy | Open Market | 104,166 | $1000K | 9/4/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 5,062 | $41K | 8/17/2026 |
| Redmile Group, LLC | ▲ Buy | Option Exercise | 195,211 | — | 7/22/2026 |
| Redmile Group, LLC | ▼ Sell | Tax Withholding | 60 | — | 7/22/2026 |
| Brian N. Cherry | ▲ Buy | Grant | 24,000 | $0 | 6/11/2026 |
| William K. Heiden | ▲ Buy | Grant | 12,000 | $0 | 6/9/2026 |
| Matthew K. Fust | ▲ Buy | Grant | 12,000 | $0 | 6/9/2026 |
| Gregory Austin Ciongoli | ▲ Buy | Grant | 12,000 | $0 | 6/9/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 5,241 | $48K | 5/18/2026 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 2,414 | $22K | 5/18/2026 |
| EcoR1 Capital, LLC | ▲ Buy | Open Market | 507,407 | $4.7M | 5/7/2026 |
| Panacea Innovation Ltd | ▼ Sell | Open Market | 313,446 | $3.2M | 5/7/2026 |
| Panacea Innovation Ltd | ▲ Buy | Option Exercise | 259,163 | $26 | 3/17/2026 |
| Panacea Innovation Ltd | ▼ Sell | Tax Withholding | 5 | $26 | 3/17/2026 |
| AnhCo Nguyen | ▲ Buy | Grant | 81,100 | $0 | 3/9/2026 |
| Yanina Grant-Huerta | ▲ Buy | Grant | 20,300 | $0 | 3/9/2026 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 24 | $122 | 3/2/2026 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 1,603 | $8K | 3/2/2026 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 377 | $2K | 3/2/2026 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 100 | $508 | 3/2/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 198 | $1K | 3/2/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 58 | $295 | 3/2/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,298 | $7K | 3/2/2026 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,442 | $7K | 3/2/2026 |
| Panacea Innovation Ltd | ▼ Sell | Open Market | 80,554 | $489K | 1/12/2026 |
| Panacea Innovation Ltd | ▲ Buy | Option Exercise | 48,737 | $5 | 11/28/2025 |
| Panacea Innovation Ltd | ▼ Sell | Tax Withholding | 1 | $14 | 11/28/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 2,859 | $38K | 11/17/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 56 | $739 | 11/17/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 1,645 | $22K | 11/17/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 85 | $1K | 11/17/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 74 | $976 | 11/17/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 57 | $662 | 8/18/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,281 | $15K | 8/18/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,620 | $19K | 8/18/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 55 | $638 | 8/18/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 86 | $999 | 8/18/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 1,668 | $19K | 8/18/2025 |
| Panacea Innovation Ltd | ▲ Buy | Open Market | 55,000 | $670K | 8/15/2025 |
| Panacea Innovation Ltd | ▲ Buy | Open Market | 19,335 | $186K | 7/17/2025 |
| Carol Giltner Gallagher | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| Matthew K. Fust | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| Pascal Touchon | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| Maria Grazia Roncarolo | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| Ameet Mallik | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| William K. Heiden | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 |
| Yanina Grant-Huerta | ▼ Sell | Open Market | 2,218 | $15K | 5/16/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 3,276 | $22K | 5/16/2025 |
| Adiumentum Capital Fund I LP | ▲ Buy | Grant | 75,572 | $500K | 5/16/2025 |
| AnhCo Nguyen | ▼ Sell | Open Market | 3,331 | $23K | 3/3/2025 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,211 | $8K | 3/3/2025 |
| Jill Henrich | ▼ Sell | Open Market | 1,059 | $7K | 3/3/2025 |
| Eric J. Hyllengren | ▲ Buy | Grant | 34,050 | $0 | 1/27/2025 |
| Jill Henrich | ▼ Sell | Open Market | 1,000 | $11K | 11/18/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,364 | $15K | 11/18/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,664 | $19K | 11/18/2024 |
| AnhCo Nguyen | ▲ Buy | Grant | 45,000 | $0 | 9/9/2024 |
| Pascal Touchon | ▼ Sell | Open Market | 2,762 | $18K | 8/16/2024 |
| Pascal Touchon | ▼ Sell | Open Market | 276 | $2K | 8/16/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 1,468 | $10K | 8/16/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 297 | $2K | 8/16/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 56 | $371 | 8/16/2024 |
| Murugan Amar | ▼ Sell | Open Market | 877 | $6K | 8/16/2024 |
| Murugan Amar | ▼ Sell | Open Market | 192 | $1K | 8/16/2024 |
| Murugan Amar | ▼ Sell | Open Market | 89 | $590 | 8/16/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,041 | $7K | 8/16/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 29 | $192 | 8/16/2024 |
| Jill Henrich | ▼ Sell | Open Market | 831 | $6K | 8/16/2024 |
| Jill Henrich | ▼ Sell | Open Market | 132 | $875 | 8/16/2024 |
| Pascal Touchon | ▼ Sell | Open Market | 81,506 | $50K | 5/16/2024 |
| Murugan Amar | ▼ Sell | Open Market | 32,401 | $20K | 5/16/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 28,648 | $18K | 5/16/2024 |
| Jill Henrich | ▼ Sell | Open Market | 25,750 | $16K | 5/16/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 42,899 | $26K | 5/16/2024 |
| Carol Giltner Gallagher | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 |
| Matthew K. Fust | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 |
| Ameet Mallik | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 |
| Maria Grazia Roncarolo | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 |
| William K. Heiden | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 |
| Pascal Touchon | ▼ Sell | Open Market | 24,844 | $18K | 3/4/2024 |
| AnhCo Nguyen | ▼ Sell | Open Market | 10,746 | $8K | 3/4/2024 |
| Murugan Amar | ▼ Sell | Open Market | 10,044 | $7K | 3/4/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 5,217 | $4K | 3/4/2024 |
| Jill Henrich | ▼ Sell | Open Market | 3,879 | $3K | 3/4/2024 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,462 | $1K | 3/4/2024 |
| Murugan Amar | ▲ Buy | Grant | 475,000 | $0 | 1/8/2024 |
| Eric J. Hyllengren | ▲ Buy | Grant | 475,000 | $0 | 1/8/2024 |
| Jill Henrich | ▲ Buy | Grant | 450,000 | $0 | 1/8/2024 |
| AnhCo Nguyen | ▲ Buy | Grant | 675,000 | $0 | 1/8/2024 |
| Pascal Touchon | ▲ Buy | Grant | 1,280,000 | $0 | 1/8/2024 |
| Pascal Touchon | ▼ Sell | Open Market | 20,409 | $8K | 11/16/2023 |
| AnhCo Nguyen | ▼ Sell | Open Market | 8,856 | $3K | 11/16/2023 |
| Murugan Amar | ▼ Sell | Open Market | 8,307 | $3K | 11/16/2023 |
| Joshi Manher | ▼ Sell | Open Market | 12,287 | $5K | 11/16/2023 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 11,958 | $5K | 11/16/2023 |
| Jill Henrich | ▼ Sell | Open Market | 3,267 | $1K | 11/16/2023 |
| Carol Giltner Gallagher | ▲ Buy | Open Market | 90,980 | $28K | 11/14/2023 |
| Carol Giltner Gallagher | ▲ Buy | Open Market | 179,020 | $40K | 11/13/2023 |
| William K. Heiden | ▲ Buy | Open Market | 100,000 | $25K | 11/10/2023 |
| Eric Dobmeier | ▲ Buy | Open Market | 446,825 | $101K | 11/10/2023 |
| Jill Henrich | ▼ Sell | Open Market | 558 | $923 | 8/16/2023 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 6,408 | $11K | 8/16/2023 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,778 | $3K | 8/16/2023 |
| Murugan Amar | ▼ Sell | Open Market | 5,050 | $8K | 8/16/2023 |
| Murugan Amar | ▼ Sell | Open Market | 3,622 | $6K | 8/16/2023 |
| AnhCo Nguyen | ▼ Sell | Open Market | 9,277 | $15K | 8/16/2023 |
| Joshi Manher | ▼ Sell | Open Market | 3,202 | $5K | 8/16/2023 |
| Joshi Manher | ▼ Sell | Open Market | 3,773 | $6K | 8/16/2023 |
| Jill Henrich | ▼ Sell | Open Market | 2,788 | $5K | 8/16/2023 |
| Pascal Touchon | ▼ Sell | Open Market | 21,432 | $35K | 8/16/2023 |
| Pascal Touchon | ▼ Sell | Open Market | 9,334 | $15K | 8/16/2023 |
| AnhCo Nguyen | ▼ Sell | Open Market | 5,849 | $10K | 8/16/2023 |
| Pascal Touchon | ▼ Sell | Open Market | 14,291 | $24K | 6/27/2023 |
| Carol Giltner Gallagher | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Matthew K. Fust | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Ameet Mallik | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Eric Dobmeier | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| William K. Heiden | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Maria Grazia Roncarolo | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Beth C. Seidenberg | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 |
| Murugan Amar | ▼ Sell | Open Market | 7,404 | $15K | 5/16/2023 |
| Murugan Amar | ▼ Sell | Open Market | 985 | $2K | 5/16/2023 |
| Banard Charlene A. | ▼ Sell | Open Market | 19,040 | $39K | 5/16/2023 |
| Pascal Touchon | ▼ Sell | Open Market | 29,766 | $61K | 5/16/2023 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 6,199 | $13K | 5/16/2023 |
| Eric J. Hyllengren | ▼ Sell | Open Market | 1,719 | $4K | 5/16/2023 |
| Dupont Jakob | ▼ Sell | Open Market | 5,074 | $18K | 3/2/2023 |
| Pascal Touchon | ▼ Sell | Open Market | 15,679 | $57K | 3/2/2023 |
| Murugan Amar | ▼ Sell | Open Market | 4,221 | $15K | 3/2/2023 |
| Koppikar Utpal | ▼ Sell | Open Market | 6,871 | $25K | 3/2/2023 |
| Dupont Jakob | ▲ Buy | Grant | 141,328 | $0 | 3/1/2023 |
| Murugan Amar | ▲ Buy | Grant | 155,375 | $0 | 3/1/2023 |
| Banard Charlene A. | ▲ Buy | Grant | 139,700 | $0 | 3/1/2023 |
| Pascal Touchon | ▲ Buy | Grant | 324,711 | $0 | 3/1/2023 |
| Koppikar Utpal | ▼ Sell | Open Market | 2,485 | $14K | 2/7/2023 |
| Dupont Jakob | ▼ Sell | Open Market | 1,124 | $5K | 11/16/2022 |
| Pascal Touchon | ▼ Sell | Open Market | 15,591 | $70K | 11/16/2022 |
| Murugan Amar | ▼ Sell | Open Market | 3,612 | $16K | 11/16/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 5,172 | $23K | 11/16/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 1,083 | $5K | 11/16/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 3,218 | $14K | 11/16/2022 |
| Pascal Touchon | ▼ Sell | Open Market | 14,806 | $75K | 8/16/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 4,124 | $21K | 8/16/2022 |
| Murugan Amar | ▼ Sell | Open Market | 1,196 | $6K | 8/16/2022 |
| Murugan Amar | ▼ Sell | Open Market | 2,234 | $11K | 8/16/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 5,940 | $30K | 8/16/2022 |
| Pascal Touchon | ▼ Sell | Open Market | 14,220 | $102K | 6/27/2022 |
| Matthew K. Fust | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Eric Dobmeier | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Beth C. Seidenberg | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Maria Grazia Roncarolo | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| William K. Heiden | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Ronald C. Renaud Jr. | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Carol Giltner Gallagher | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Ameet Mallik | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Roy D. Baynes | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 5,853 | $33K | 6/8/2022 |
| Murugan Amar | ▼ Sell | Open Market | 906 | $5K | 5/17/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 4,616 | $25K | 5/17/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 966 | $5K | 5/17/2022 |
| Pascal Touchon | ▼ Sell | Open Market | 13,913 | $74K | 5/17/2022 |
| Murugan Amar | ▼ Sell | Open Market | 2,317 | $12K | 5/17/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 3,873 | $21K | 5/17/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 2,272 | $22K | 3/1/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 1,491 | $15K | 3/1/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 2,221 | $22K | 3/1/2022 |
| Pascal Touchon | ▲ Buy | Grant | 180,565 | $0 | 3/1/2022 |
| Kristin Yarema | ▲ Buy | Grant | 45,533 | $0 | 3/1/2022 |
| Koppikar Utpal | ▲ Buy | Grant | 61,235 | $0 | 3/1/2022 |
| Dupont Jakob | ▲ Buy | Grant | 78,506 | $0 | 3/1/2022 |
| Pascal Touchon | ▼ Sell | Open Market | 8,828 | $87K | 3/1/2022 |
| Murugan Amar | ▲ Buy | Grant | 51,814 | $0 | 3/1/2022 |
| Murugan Amar | ▼ Sell | Open Market | 1,465 | $14K | 3/1/2022 |
| Murugan Amar | ▼ Sell | Open Market | 1,112 | $11K | 3/1/2022 |
| Dupont Jakob | ▲ Buy | Option Exercise | 5,000 | $48K | 2/10/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 5,000 | $80K | 2/10/2022 |
| Koppikar Utpal | ▼ Sell | Open Market | 2,496 | $36K | 2/7/2022 |
| Dupont Jakob | ▲ Buy | Option Exercise | 5,000 | $48K | 1/3/2022 |
| Dupont Jakob | ▼ Sell | Open Market | 5,000 | $80K | 1/3/2022 |
| Dupont Jakob | ▲ Buy | Option Exercise | 5,000 | $48K | 12/1/2021 |
| Dupont Jakob | ▼ Sell | Open Market | 5,000 | $90K | 12/1/2021 |
| Pascal Touchon | ▼ Sell | Open Market | 8,402 | $144K | 11/16/2021 |
| Newell Joe | ▼ Sell | Open Market | 3,332 | $57K | 11/16/2021 |
| Murugan Amar | ▼ Sell | Open Market | 2,124 | $36K | 11/16/2021 |
| Koppikar Utpal | ▼ Sell | Open Market | 3,655 | $63K | 11/16/2021 |
| Dupont Jakob | ▼ Sell | Open Market | 2,199 | $38K | 11/16/2021 |
| Newell Joe | ▼ Sell | Open Market | 7,000 | $124K | 11/15/2021 |
| Newell Joe | ▲ Buy | Option Exercise | 3,500 | $43K | 11/15/2021 |
| Matthew K. Fust | ▼ Sell | Open Market | 13,354 | $260K | 11/4/2021 |
| Dupont Jakob | ▲ Buy | Option Exercise | 5,000 | $48K | 11/2/2021 |
| Dupont Jakob | ▼ Sell | Open Market | 5,000 | $82K | 11/2/2021 |
| Newell Joe | ▲ Buy | Option Exercise | 10,500 | $128K | 9/22/2021 |
| Newell Joe | ▼ Sell | Open Market | 10,500 | $179K | 9/22/2021 |
| Newell Joe | ▼ Sell | Open Market | 3,116 | $49K | 9/15/2021 |
| Newell Joe | ▼ Sell | Open Market | 3,500 | $53K | 8/30/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.